Cargando…
Development and Validation of an UPLC-MS/MS Method for Pharmacokinetic Comparison of Five Alkaloids from JinQi Jiangtang Tablets and Its Monarch Drug Coptidis Rhizoma
JinQi Jiangtang (JQJT) tablets, a Chinese patent medicine approved by the State Food and Drug Administration, are composed of Coptidis Rhizoma, Astragali Radix, and Lonicerae Japonicae Flos, and have a significant effect on diabetes. Coptidis Rhizoma is monarch drug in the prescription. The aim of t...
Autores principales: | Sun, Lili, Ding, Feifei, You, Guangjiao, Liu, Han, Wang, Meng, Ren, Xiaoliang, Deng, Yanru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874817/ https://www.ncbi.nlm.nih.gov/pubmed/29286316 http://dx.doi.org/10.3390/pharmaceutics10010004 |
Ejemplares similares
-
JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial
por: Cao, Hongbo, et al.
Publicado: (2010) -
JinQi Jiangtang Tablet Regulates Gut Microbiota and Improve Insulin Sensitivity in Type 2 Diabetes Mice
por: Cao, Ying, et al.
Publicado: (2019) -
The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design
por: Sun, Xiao, et al.
Publicado: (2015) -
Renoprotective effect of JinQi-JiangTang tablet on high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats
por: Jiang, Bingjie, et al.
Publicado: (2018) -
The Hypoglycemic Effect of JinQi Jiangtang Tablets Is Partially Dependent on the Palmatine-Induced Activation of the Fibroblast Growth Factor Receptor 1 Signaling Pathway
por: Li, Siming, et al.
Publicado: (2022)